How to Choose a CRO for the Upcoming 2026 ISO 10993-1 Update

Selecting the right contract research organization (CRO) is a critical decision for any medical device manufacturer, but this choice becomes even more crucial in the face of evolving international standards. With the anticipated revision of ISO 10993-1 expected in 2026, the foundational standard for biological evaluation of medical devices is set to undergo significant updates. Manufacturers must ensure their testing partners are not just aware of these changes but are proactively preparing their systems, methodologies, and personnel to meet heightened regulatory expectations. Simply accepting a CRO’s assurance of future compliance is insufficient. A robust vetting process requires manufacturers to seek specific, actionable evidence of a laboratory’s readiness. This involves a deep dive into their quality management system (QMS), staff training, risk assessment frameworks, and testing protocols. A truly prepared partner will be able to demonstrate a clear strategy for adapting its Biological Evaluation Plans (BEPs), chemical characterization methods, and final reporting structures to align with the new principles long before the standard is officially published. ## Key Points * **Proactive QMS Adaptation is Non-Negotiable:** A forward-thinking CRO should already be updating its Quality Management System (QMS), including Standard Operating Procedures (SOPs) and internal training modules, to reflect the principles outlined in draft versions of the upcoming ISO 10993-1 revision. * **Demand Evidence, Not Just Promises:** Move beyond verbal assurances. Request concrete evidence of readiness, such as a documented transition plan, summaries of updated SOPs, or anonymized training records for key scientific staff. * **Scrutinize the Biological Evaluation Strategy:** A prepared lab will have already re-evaluated its approach to creating Biological Evaluation Plans (BEPs). Inquire how they plan to integrate new endpoints, address new risk considerations, and justify testing strategies under the revised framework. * **Assess Technical Protocol Alignment:** Ask specific questions about how the CRO plans to adapt key test protocols, such as chemical characterization (ISO 10993-18), to meet potentially more stringent requirements and align with the principles of the 3Rs (Replacement, Reduction, and Refinement of animal testing). * **Reporting and Documentation Readiness:** The structure and content of final biocompatibility reports will likely face increased scrutiny. A qualified CRO should be able to articulate how its report templates and data presentation will be enhanced to clearly meet the new standard's documentation requirements. * **Expertise is Key:** The most valuable partners will have senior toxicologists and biocompatibility experts actively participating in industry working groups or closely monitoring standards committees. Their direct involvement provides foresight that cannot be matched by labs that are merely waiting for the final publication. ## Beyond "We're Aware": A Deep Dive into Vetting a CRO's Readiness Verifying a CRO's preparedness for the 2026 ISO 10993-1 update requires a multi-faceted evaluation that goes far beyond surface-level questions. Manufacturers should structure their audit or qualification process around three core pillars: Quality System Preparedness, Strategic and Methodological Alignment, and Technical Execution. ### 1. Assessing Quality Management System (QMS) Preparedness An accredited QMS (e.g., to ISO 17025) is the baseline, not the goal. The real differentiator is how the CRO is proactively modifying that system for the future. **Key Questions for QMS Evaluation:** * **Transition Plan:** "Can you provide a summary of your formal transition plan for adopting the revised ISO 10993-1 standard? What are the key milestones and timelines?" A prepared CRO will have a documented plan, not just a vague intention. * **SOP Updates:** "Which key SOPs related to biological risk assessment, BEP development, and test execution have been identified for revision? What is the timeline for drafting, approving, and implementing these changes?" * **Staff Training and Competency:** "What specific training has your scientific and technical staff (especially study directors and toxicologists) received on the draft revisions of ISO 10993-1? Can you provide anonymized training records or a summary of the training content?" Look for evidence of external seminars, internal workshops, and formal competency assessments. * **Risk Management Integration:** "How are you updating your internal risk management processes to align with the revised standard's approach to risk assessment?" This demonstrates a deep, integrated understanding rather than a superficial, checklist-based approach. ### 2. Evaluating Strategic and Methodological Alignment The new standard is expected to continue emphasizing a risk-based approach. A CRO’s ability to think strategically about biological evaluation is as important as its ability to execute a test. **Key Questions for Strategic Evaluation:** * **BEP Methodology:** "How is your approach to drafting a Biological Evaluation Plan changing? Can you describe how your BEP templates are being updated to incorporate new endpoints, material characterization data, and justifications for testing strategies?" A proactive lab will be focusing on building a more robust scientific narrative from the very beginning. * **Chemical Characterization Integration (ISO 10993-18):** "How will the results of chemical characterization be more deeply integrated into the overall risk assessment and testing plan under the new standard? How do you determine when chemistry data is sufficient to mitigate certain biological endpoints?" * **Addressing New Considerations:** "How does your team plan to assess risks for devices with novel materials, nanomaterials, or transient patient contact, which may receive more focus in the updated standard?" This tests their forward-looking expertise and scientific depth. ### 3. Drilling Down on Technical Execution and Reporting Ultimately, the quality of the data and the final report determines regulatory success. Scrutinize the CRO's plans for adapting its core technical services. **Key Questions for Technical Evaluation:** * **Test Protocol Adjustments:** "For key tests like *in vitro* cytotoxicity or sensitization, what, if any, protocol adjustments do you anticipate based on the revised standard's principles and the broader regulatory push towards animal welfare (3Rs)?" * **Final Report Structure:** "How will the structure and content of your final biocompatibility reports be modified to meet the heightened expectations of regulatory bodies like the FDA? Will there be a greater emphasis on the toxicological risk assessment of chemical characterization data?" * **Regulatory Communication:** "Can you provide examples of how your team has successfully defended a novel testing strategy to a regulatory body in the past? How would you support us if a regulator had questions about a testing approach based on the new standard?" ## Scenario Analysis: Choosing a Biocompatibility Partner Comparing potential CROs is easier when you apply a consistent evaluation framework. Consider two hypothetical labs. ### Scenario 1: The Proactive Partner (CRO A) During the qualification audit, CRO A presents a detailed slide deck on their "ISO 10993-1:2026 Readiness Program." They provide a public-facing white paper authored by their lead toxicologist on the anticipated changes. When asked about their BEP process, they share a redacted template that includes new, dedicated sections for justifying the omission of certain tests based on a comprehensive risk assessment and material data. They confirm that all study directors completed a formal training module on the draft standard three months prior. * **What This Shows:** CRO A is not just reacting; they are investing in expertise, process improvement, and client education. They view the standard update as a core business priority and can provide tangible evidence of their preparation. This significantly de-risks the manufacturer's regulatory submissions. ### Scenario 2: The Reactive Lab (CRO B) When asked about the upcoming standard, CRO B’s representative states, "We are monitoring the situation closely and will be fully compliant when the new version is released. We are ISO 17025 accredited and have been doing this for 20 years." They cannot provide a documented transition plan or evidence of specific staff training. Their sample BEP follows a traditional, test-focused template without a deep risk analysis. * **What This Shows:** CRO B is taking a passive, wait-and-see approach. While they may eventually become compliant, relying on them introduces significant risk. They may be unprepared for the nuanced interpretations required by the new standard, potentially leading to requests for additional information (AIs) from regulators, project delays, and unexpected costs. ## Strategic Considerations and the Role of Q-Submission Choosing a proactive, well-prepared CRO is a critical risk mitigation strategy. A knowledgeable testing partner can help identify potential biocompatibility gaps early, develop more efficient and scientifically sound testing plans, and produce documentation that is built to withstand regulatory scrutiny. For devices with novel materials, complex manufacturing processes, or borderline classifications, early engagement with the FDA is paramount. The Q-Submission program provides a formal pathway to get feedback on your proposed testing strategy before submission. A top-tier CRO can be an invaluable partner in this process by helping to prepare the briefing package and formulate scientifically sound questions for the FDA. Their expertise can help ensure that the proposed biological evaluation strategy is aligned with current FDA guidance and expectations, increasing the likelihood of a productive pre-submission meeting. ## Finding and Comparing Biocompatibility Testing Services Providers When selecting a provider, it is essential to compare multiple options based on the criteria discussed above. Look for a partner whose expertise matches your device's specific needs. Key factors to consider include: * **Technical Expertise:** Does the lab have documented experience with your device type and materials? * **Regulatory Track Record:** Can they speak to their experience with submissions to your target regulatory bodies (e.g., FDA, EU Notified Bodies)? * **Communication and Project Management:** Is their team responsive, transparent, and easy to work with? * **Demonstrated Preparedness:** Do they provide clear, convincing evidence of their readiness for upcoming standards like ISO 10993-1:2026? Using a dedicated directory can streamline the process of identifying and vetting qualified labs. To find qualified vetted providers [click here](https://cruxi.ai/regulatory-directories/biocompatibility_testing) and request quotes for free. ## Key FDA references When planning a biological evaluation program for submission in the United States, sponsors should be familiar with the general regulatory framework and key guidance documents. While specific standards like ISO 10993-1 are central, they are applied within the context of FDA regulations. * **FDA Guidance: Use of International Standard ISO 10993-1, 'Biological evaluation of medical devices - Part 1: Evaluation and testing within a risk management process.'** This is the primary guidance document outlining the FDA's expectations for biocompatibility and how the agency interprets the ISO standard. * **21 CFR Part 58 – Good Laboratory Practice for Nonclinical Laboratory Studies.** This regulation outlines the requirements for conducting nonclinical studies that support regulatory submissions, ensuring data quality and integrity. * **FDA's Q-Submission Program Guidance.** This document provides the procedural details for sponsors wishing to engage with the FDA to get feedback on their regulatory and testing strategies prior to a formal marketing submission. --- This article is for general educational purposes only and is not legal, medical, or regulatory advice. For device-specific questions, sponsors should consult qualified experts and consider engaging FDA via the Q-Submission program. --- *This answer was AI-assisted and reviewed for accuracy by Lo H. Khamis.*